Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD
Gene Therapy Company Calls Off Diabetic Macular Edema Program
Executive Summary
Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.